Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

Abstract Introduction: Hepatocellular carcinoma (HCC) remains a significant global public health risk, and its mortality rate remains high. Tetrandrine (TET) inhibits tumor growth, but its combination with anti-PD-1 im...

www.frontiersin.org

Zum Originalartikel